Oncology

Latest News

Tech Updates: McKesson Launches Precision Oncology Consortium; Financing for RISA Labs PA Platform

By Mary Caffrey

April 17th 2025

These advances are designed to improve uptake of biomarker-driven cancer care and reduce treatment delays.

Making Novel Cancer Therapies Available Requires Choices Because Resources Are Limited

By Kyle Munz

April 14th 2025

Businessman shows medical network wooden block for health, medicine, insurance, healthcare, care, concept. Medical technology services to solve public - ภัทรชัย รัตนชัยวงค์ - stock.adobe.com.jpeg

NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer

By Giuliana Grossi

April 9th 2025

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Woman with keloid on shoulder | Image credit: weerajata – stock.adobe.com

Deep Learning Tool Differentiates Keloids From Malignant Lesions Without Dermoscopy

By Hayden E. Klein

April 2nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 5th 2014

Ariad's Investigational NSCLC Drug: Breakthrough by FDA

The molecule is being evaluated in crizotinib-resistant ALK-positive NSCLC patients. The results from the phase 1/2 trial with AP26113 were presented at the 2014 European Cancer Congress.

October 4th 2014

JCO Study: MMA Did Not Influence Fee-For-Service Prescribing

The study by Kaiser Permanente found that prescription practices were not much influenced by the decrease in fee-for-service payments for outpatient chemotherapy, due the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

October 4th 2014

Cigna Refers to NCCN Guidelines for Oncology Coverage Decisions

The Cigna-NCCN collaboration will benefit about 12.5 million members.

October 4th 2014

Merck's HPV Vaccine Effective Against 9 Subtypes

The study, conducted in Austria, evaluated the potency of the 9-valent vaccine in preventing the development of cervical precancer in women infected with HPV.

October 3rd 2014

Ambiguous Mammograms: An Emotional and Financial Burden

A study published in a supplement to the Journal of Women's Health looks to the widespread impact of newer screening technologies to improve outcomes.

October 3rd 2014

Value Discussion Reemerges at NICE: Roche's Gazyvaro Rejected

Following Kadcyla, NICE has now rejected another drug from Roche: Gazyvaro for CLL, citing ambiguities in the company's filing and the high cost.

October 3rd 2014

Literature: Germline BRCA Mutations Increase Susceptibility to Salivary Gland Cancer

The study, published online in JAMA Otolaryngology - Head & Neck Surgery, found a significant increase in the rate of head and neck cancers in individuals carrying a BRCA mutation.

October 2nd 2014

New Receptor Target for Glioblastoma Multiforme Holds Promise

A review published in Neuro-Oncology provides insight into some of the molecules being developed to target IL13RÎ±2 in brain tumors.

October 1st 2014

ASCO: Obesity a Risk Factor and Complication in Cancer

ASCO has called for raising awareness to control obesity, as it is not just a risk factor for developing diabetes but also for cancer.

September 30th 2014

ESMO 2014: New Regimen for BRAF-mutated Melanoma

Results from 2 phase 3 trials showed better response rates, progression-free survival, and overall survival when a BRAF inhibitor was combined with a MEK inhibitor, compared with a BRAF inhibitor alone.

September 30th 2014

Segment 11 - Why It Is an Exciting Time for Immuno-Oncology

The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.

September 30th 2014

Segment 10 - Paying for Combination Therapies

Michael Kolodziej, MD, considers the benefit of combination therapy vs sequential and whether the increased toxicity of combination therapy is worth it.

September 30th 2014

Segment 9 - Safety Concerns with Oncolytic Virus Therapies

Although the oncolytic virus therapy being used in the OPTIM trial has been modified in a way that there should be minimal safety concerns, it should still be handled in a way to limit adverse effects and mutations, according to Kimberly Shafer-Weaver, PhD.

September 30th 2014

Segment 8 - Overall Survival and Ongoing Combination Clinical Trials

While it would be nice to think that one and only one therapy would be effective at combatting cancer, combination therapy is needed, Kimberly Shafer-Weaver, PhD, said.

September 30th 2014

Segment 7 - Ultimate Measures of Efficiency in Immuno-Oncology

People are now viewing cancer as a kind of chronic disease that can be held at bay, if it cannot be eliminated entirely, according to Kimberly Shafer-Weaver, PhD.

September 30th 2014

Segment 6 - Including Patient-Reported Outcomes

Although there are some efforts to marry progression-free survival benefits to clinical benefits defined by the patients, the approach is still in the early stages and needs to be moved forward more quickly, according to Michael Kolodziej, MD.

September 30th 2014

Segment 5 - Establishing the Value of Immunotherapy in Oncology

Michael Kolodziej, MD, explains, the benefit of using biomarkers from a payer perspective to ensure that the right patient gets the right treatment.

September 30th 2014

Segment 4 - From Animal Models to Human Bodies

Although animal models have shown the anti-CTLA-4 antibodies boost the immune system, the human body is not so simple, Jianda Yuan, MD, PhD, said.

September 30th 2014

Segment 3 - Pairing Patients with the Right Therapies

In this clip, Kimberly Shafer-Weaver, PhD, discusses specific biomarkers that could establish utilities for specific patient populations and measuring response to drugs.

September 30th 2014

Segment 2 - Bringing Latest Innovations to the Public

Jianda Yuan, MD, PhD, explains the importance of bringing the latest innovations to the public and how more data are showing promising immunologic and clinical responses for different types of cancer.

September 30th 2014

Segment 1 - Immuno-Oncology Education Outreach Efforts

Surabhi Dangi-Garimella, PhD, managing editor of The American Journal of Managed Care's Evidence-Based series led the panel of experts in a discussion on immuno-oncology by first talking about checkpoint inhibitors currently in the market and under development.

September 30th 2014

ESMO 2014: Anamorelin Improves Quality of Life in Lung Cancer Patients

Phase 3 trial data from the ROMANA trials, presented at ESMO found that anamorelin improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia.

September 29th 2014

Xalkori to Treat ROS1-Mutated Lung Cancer Patients?

Xalkori, currently approved for treating NSCLC with ALK rearrangements, reduced the tumor size in nearly 75% of the patients and also extended the remission period.

September 29th 2014

Perjeta Improves Survival in HER2-Positive Breast Cancer Patients

The monoclonal antibody extended survival by nearly 16 months compared to those in the control cohort.

September 29th 2014

ESMO 2014: Nivolumab Promise in Melanoma

Results from the CheckMate-037 trial showed a significant increase in duration of response in patients with advanced melanoma administered nivolumab as second- or third-line therapy

September 26th 2014

Hypercalcaemia as an Early Cancer Biomarker

A study published in the British Journal of Cancer discovered a correlation between hypercalcaemia and the risk of cancer, specifically in males.

September 26th 2014

ESMO Congress: Researchers Identify Barriers to Drug Access

The researchers identified discrepancies across the globe in patient access to life-saving cures for cancer.

September 26th 2014

A New Drug Delivery Vehicle: Anthrax Bacteria

Having delivered antibody mimics to cancer cells in vitro, the research group at MIT that conducted the research is now working on evaluating the technique in tumors grown in mice.

September 25th 2014

Lung Infections May Hamper Efficacy of FDG-PET

A new retrospective study published in JAMA identified that tuberculosis and certain fungal infections in the lungs could hamper the efficient detection of lung cancer by FDG-PET imaging.

September 25th 2014

Treating Late-Stage Lung Cancer Not Cost-Effective: JTO Study

A prospective study published in The Journal of Thoracic Oncology found that the average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

...

149 150 151 152 153 154 155 156 157

...

184 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions